About
News & Events
Technologies
Applications
Strategic Partnerships
Our Products
Resource Center
Contact Us
About Us Therapeutic Technologies Renal Systems Therapeutic Technologies Medivators International
About Us Renal Systems Therapeutic Technologies Medivators International Home
TTG


Hollow Fiber Filtration

Hemocor HPH - click for full size (54k)

line

Hemocor HPH® Hemoconcentrators

From the World Leader in Hemoconcentration

Benefits of the Hemocor HPH

  • Polysulfone membrane offers excellent biocompatibility
  • Proprietary fiber manufacturing process ensures consistent performance
  • No-rinse fiber for convenient set-up
  • Complete model selection offers ultrafiltration rates for the full range of patients from the neonate to largest adult
  • Meets the biocompatibility requirements of ISO 10993-4 selection of tests, for interactions with blood
  • Manufactured under U.S. Patent 5,762,798

Proven Therapeutic Effectiveness

Using the Hemocor HPH hemoconcentrator:

  • Reduces the need for homologous blood and blood products by providing patients with their own concentrated whole blood.
  • Maintains the desired hematocrit level for oxygen transport to tissues.
  • Decreases the risk of post-operative bleeding through the retention of platelets and plasma coagulation proteins.
  • Maintains oncotic pressure by retaining plasma proteins while quickly and gently removing excess plasma water.
  • Minimizes the need for diuretic use, which may be contraindicated for some patients.

Hemoconcentration: The Treatment of Choice

The use of hemoconcentrators during cardiac bypass surgery has continued to rise rapidly. Hemoconcentration has become the preferred method of controlling hemodilution during cardiopulmonary surgery by surgeons and perfusionists throughout the world. This process is also being performed to maintain higher hematocrit levels and to reduce the need for additional blood products during and after bypass.

Convenience and Value

  • The Hemocor HPH provides perfusionists with a convenient and lower cost method of processing hemodiluted blood.
  • The “no-rinse” hemoconcentrator can be easily inserted into the extracorporeal circuit by the perfusionist at any time during the
    surgical procedure.
  • Shortened circuit assembly time is accomplished with the use of the optional standard tubing sets.
  • Costs are reduced by eliminating purchases of capital equipment and blood processing kits.

The Hemocor HPH family

The Hemocor HPH family of high performance hemoconcentrators is designed to meet the needs of both adult and pediatric patients. The high performance of the Hemocor HPH enables the perfusionist to manage the patient’s hematocrit and fluid status. The convenience of the “no-rinse” hemoconcentrator allows insertion into the extracorporeal circuit at any time during surgery without the need to rinse the unit.

Hemocor HPH hemoconcentrators are designed using glycerine-free polysulfone membranes. Such membranes have exceptional biocompatibility through a broad range of medical device applications. Their superior blood compatibility is well documented with clinical evidence.1,2 Minntech’s expertise and knowledge, accumulated from over 10 years of development, manufacturing, and clinical experience, is reflected in the quality and innovation of the Hemocor HPH family.

 

NOTES:

The HPH 1400 TS and the HPH 1000 TS each consist of a Hemocor HPH Hemoconcentrator with 36 inch (90 cm) lengths of 1/4 inch (6.35 mm) inside diameter tubing attached. The HPH 400 TS consists of a Hemocor HPH Hemoconcentrator with 18 inch (45 cm) of 1/4 inch (6.35 mm) inside diameter tubing attached. Ratchet clamps are included on each segment of tubing. Each hemoconcentrator, with tubing set, also includes two attached adapters with male luer lock ends and 1/4 inch (6.35 mm) male tubing connectors.

Other than the HCH-1 hemoconcentrator holder, all products are provided with a sterile and non-pyrogenic fluid pathway in an unopened, undamaged package.

1 Chenoweth, D.E., Cooper, SW., Hugh, T.E., et aI: Complement Activation during Cardiopulmonary Bypass: Evidence of Generation of C3a and C5a anaphylatoxins. New Engl. J. Med. 304:497-504, 1981
2 Kaplan, A.A. Toueg, S., Kennedy, T.L., Complement Kinetics during Continuous Arteriovenous Hemofiltration: Studies with a New Polysulfone Hemofilter. Blood Purification 6:27-36, 1988.
3 In vitro test results with bovine blood, end-to-end pressure drop, inlet conditions: Hct = 25%, total protein = 5 g/dl, temp = 37OC, Qb = 200 mI/min, TMP = 200 mmHg
4 In vitro test results with bovine blood, end-to-end pressure drop, inlet conditions: Hct = 32%, total protein = 6.0 gm/dl, temp = 37OC, Qb = 50 mI/min, TMP = 100 mmttg.


| Home | About Us | Renal Systems | Therapeutic Technologies | Medivators | International |

For information about this site, e-mail webmaster@minntech.com
© 2007 Minntech Corporation.   All rights reserved.
14605 28th Avenue North   Minneapolis, MN 55447   U.S.A.
Phone: (800) 328-3345, Fax: (763) 553-3387

 

link 1